Lv78
4400 积分 2023-05-29 加入
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
5天前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
5天前
已完结
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia
12天前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
26天前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
27天前
已关闭
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
1个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
1个月前
已完结
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906
1个月前
已完结
Prevalence, incidence, and definition of severe hypertriglyceridemia: A comprehensive review and weighted summary
1个月前
已完结
皖公网安备34019202002308
